Clearmind Medicine to Partner with Microdose for Psychedelic Capital: Mar 2022 Today, Thursday, March 24th

Posted: March 25, 2022 at 2:21 am

TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announced that its CEO, Dr. Adi Zuloff-Shani and Mark Haden, VP Business Development, will be presenting in the Psychedelic Capital: March 2022 virtual event.

Link:
Clearmind Medicine to Partner with Microdose for Psychedelic Capital: Mar 2022 Today, Thursday, March 24th

Related Posts